Families Raise Funds to Treat Rare Genetic Disorder
Four American families are urgently trying to raise $1.15 million to save their children from a devastating genetic disease. While treatments are available, the financial burden falls on them to fund clinical trials. Each family has a child diagnosed with spastic paraplegia 50 (SPG50), a rare neurological disorder affecting fewer than 100 people globally.
In an interview, families expressed their race against time to secure necessary treatments. Their target is to gather the funds by the end of October to commence trials in the United States.
Understanding SPG50
SPG50 hinders children’s development, according to information from the National Rare Disability Agency. Symptoms can include cognitive impairment, muscle weakness, speech difficulties, and eventually, paralysis.
Dr. Eve Elizabeth Penney, an epidemiologist, noted that SPG50 generally progresses at different rates for each individual. Children may face early developmental delays and eventual mobility challenges.
No treatments are FDA-approved for SPG50. However, a Canadian father, Terry Pirovolakis, whose son was diagnosed with the disease, created a gene therapy that shows promise.
Parents’ Journeys
Pirovolakis shared that he was initially advised to accept his son’s fate—being paralyzed from the waist down by age ten. Instead, he dedicated himself to finding a solution, using his savings to consult experts and develop a gene therapy.
His son received the therapy in March 2022 and is now thriving. Following this, Pirovolakis initiated phase 2 studies in the U.S. involving three additional children, all of whom have seen a halt in disease progression and improvements in cognition.
Four Families, One Shared Struggle
Rebekah Lockard from Colorado faces the daunting task of treating her four-year-old daughter, Naomi, diagnosed in 2023 with SPG50. Her younger son, Jack, also has the condition and has received previous treatment.
Lockard explained that while Naomi uses a wheelchair for mobility, Jack can move around more easily. “Every day, I’m thankful Jack got meaningful treatment as a young child, but it weighs heavily that Naomi hasn’t had the same chance,” she remarked.
Emma and Dylan Jobs from Arkansas also dread the future for their son Cade, diagnosed in 2023. “Without treatment, he risks losing his ability to walk,” Emma lamented. They live in constant fear that he may regress without intervention.
Jordan and Cody Medeiros, from Oregon, are heartbroken over the slow decline of their four-year-old son, Lincoln, who has been diagnosed with SPG50 for two years. “He falls often and can’t express his pain,” Jordan said. “Knowing there are treatments available that can help but are out of reach is just frustrating.”
A Glimmer of Hope
In Pennsylvania, Jamie and Cody Wood celebrated their twin daughters’ birth in 2022. Shortly after, one was diagnosed with SPG50. Yet, a bittersweet milestone occurred when Mira took her first step three weeks later. “We know only one treatment exists for her,” Jami said. “Without it, she risks losing so much.”
Despite the struggles, there is hope for the future. Should the ongoing phase 3 trials succeed, the drug could become FDA-approved, allowing for broader insurance coverage and potentially eradicating the disease from newborn screenings.
Pirovolakis is committed to working with the FDA, but he acknowledges that the approval process isn’t straightforward. He emphasized the need for flexibility regarding ultra-rare conditions like SPG50, which struggle against the stringent manufacturing standards typically applied.
For those interested in SPG50 and the families’ journeys, further information can be found on the Jack’s Corner website.
The urgency and emotional weight of these families’ experiences showcase both their resilience and the complexities surrounding rare diseases and their treatments.
